Dr Caio Rocha Lima speaks to ecancer about the phase III COMMIT trial, combining atezolizumab with FOLFOXIRI plus bevacizumab significantly improved outcomes compared with atezolizumab alone in treatment-naïve dMMR/MSI-H metastatic colorectal cancer.

Dr Rocha Lima highlights that at interim analysis, FFX/bev + atezolizumab reduced the risk of progression by 56% (HR 0.44; P=0.0103), with a median PFS of 30.0 months versus 4.3 months for atezolizumab monotherapy.

Objective response and disease control rates were also substantially higher with the combination, though with increased grade ≥3 adverse events.

Dr Rocha Lima concludes by saying that these results support dual immunotherapy and VEGF inhibition with chemotherapy as a more effective frontline strategy in dMMR/MSI-H mCRC.